The primary objective of this study is to characterize the pharmacokinetics of TV-45070 in plasma following single and multiple-dose topical application of 8% TV-45070 ointment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Enrollment
45
Teva Investigational Site 12961
Lenexa, Kansas, United States
Plasma concentrations
Time frame: Day 8
Drug level in skin
Time frame: Days 1, 8, 15, 22, 29
Excretion of drug in urine
Time frame: Day 8
Identification of metabolites in blood
Time frame: Days 8, 10
Identification of metabolites in urine
Time frame: Day 8
Identification of metabolites in skin
Time frame: Days 1, 8, 15, 22, 29
Intraepidermal nerve fiber density in skin
Time frame: Days 1, 8, 15, 29
Percentage of Participants with Adverse Events
Time frame: 10 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.